Who knows exactly but a look back through the threads around the time of cap raises may shed some light.
otherwise bing says:
Certainly! While the **Lassonde Curve** is most commonly associated with the mining industry, there isn't a direct equivalent specifically tailored for junior biotech companies. However, let's explore how the Lassonde Curve concept could be adapted to the biotech sector.1. **Exploration Stage (Biotech Equivalent)**: - In the exploration phase, junior biotech companies are akin to early-stage startups. They focus on research, development, and discovery of novel drugs, therapies, or medical technologies. - During this stage, excitement builds as promising results from preclinical studies or initial clinical trials are announced. Investors may assign value based on the potential of the company's pipeline. - **Example**: Imagine a junior biotech company that discovers a groundbreaking treatment for a rare disease. The stock value climbs as anticipation grows.2. **Technical Evaluation (Biotech Equivalent)**: - In the technical evaluation phase, biotech companies move beyond initial discovery and delve into clinical trials. Engineers (in this case, scientists and clinicians) join the journey. - Clinical trials (Phase I, II, and III) are conducted to assess safety, efficacy, and dosing. These studies take time, and new information releases may be scarce. - If challenges arise during trials or if results are less favorable than expected, stock value may decline. Real-world complexities become apparent. - **Example**: A biotech company's promising drug candidate faces unexpected side effects during Phase II trials, leading to investor caution.3. **Production Decision (Biotech Equivalent)**: - This stage corresponds to when clinical trials are largely completed, and regulatory approvals are pending. Strategic partnerships and funding become critical. - Biotech companies seek collaborations with larger pharmaceutical firms or secure funding for late-stage trials and commercialization. - Financing challenges or regulatory hurdles can extend this phase indefinitely. - **Example**: A biotech company with a successful Phase III trial seeks FDA approval for its cancer drug. The stock price reflects investor confidence in the upcoming decision.4. **Commercialization (Biotech Equivalent)**: - While not directly part of the Lassonde Curve, we can extend it to include the commercialization phase. - Successful regulatory approvals lead to product launch, marketing, and sales efforts. Revenue generation becomes the focus. - Companies transition from junior status to established players. - **Example**: Our biotech company's drug receives FDA approval, enters the market, and starts generating revenue. Stock value reflects market adoption and sales performance.Remember that this adaptation is conceptual, and the biotech industry has unique dynamics. The Lassonde Curve serves as a useful framework for understanding the life stages of resource-based companies, but applying it to biotech requires some creative interpretation. For more detailed insights, you might want to explore industry-specific metrics and case studies related to junior biotech companies.Source: Conversation with Bing, 3/7/2024(1) Mining's Lassonde Curve - A Wild Ride - kuchling.com. https://kuchling.com/the-lassonde-curve-a-wild-ride/.(2) Visualizing the Life Cycle of a Mineral Discovery. https://www.visualcapitalist.com/visualizing-the-life-cycle-of-a-mineral-discovery/.(3) Crescat Uses Lassonde Curve Industry Expertise in BC’s Golden Triangle. https://www.streetwisereports.com/article/2021/09/27/crescat-uses-lassonde-curve-insider-expertise-in-bc-s-golden-triangle.html.
CHM Price at posting:
3.0¢ Sentiment: Buy Disclosure: Held
(20min delay)